On January 16, 2020, the European Patent Office (EPO) Board of Appeal dismissed the appeal for the CRISPR patent, which covers gene-editing technology, upholding the EPO’s Opposition Division’s decision to revoke the patent for lack of novelty. Law360 quoted Finnegan’s European IP Blog in its article: “The key message to take away is that ensuring priority is claimed validly is crucial. To avoid any issues at the EPO, applicants must make sure that they have the right to claim priority at the application filing date."
Read the full article here.
Media Mention
Women in Business Law Americas Awards 2024: Three Finnegan Attorneys Shortlisted
April 7, 2024
Press Release
Finnegan and BMW Group Successfully Demolish Non-Practicing Entity NorthStar’s Efforts
April 3, 2024
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.